NVO vs. MRK
Compare and contrast key facts about Novo Nordisk A/S (NVO) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVO or MRK.
Correlation
The correlation between NVO and MRK is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVO vs. MRK - Performance Comparison
Key characteristics
NVO:
-0.59
MRK:
-0.61
NVO:
-0.61
MRK:
-0.71
NVO:
0.91
MRK:
0.90
NVO:
-0.47
MRK:
-0.47
NVO:
-1.25
MRK:
-0.94
NVO:
16.88%
MRK:
13.50%
NVO:
35.89%
MRK:
20.85%
NVO:
-71.31%
MRK:
-68.62%
NVO:
-43.24%
MRK:
-23.15%
Fundamentals
NVO:
$361.90B
MRK:
$253.19B
NVO:
$2.93
MRK:
$4.78
NVO:
28.30
MRK:
20.94
NVO:
1.24
MRK:
0.07
NVO:
$204.72B
MRK:
$48.59B
NVO:
$173.22B
MRK:
$36.68B
NVO:
$108.42B
MRK:
$19.73B
Returns By Period
In the year-to-date period, NVO achieves a -3.43% return, which is significantly lower than MRK's 1.23% return. Over the past 10 years, NVO has outperformed MRK with an annualized return of 16.48%, while MRK has yielded a comparatively lower 8.57% annualized return.
NVO
-3.43%
-23.09%
-35.86%
-21.28%
24.12%
16.48%
MRK
1.23%
0.64%
-17.76%
-12.43%
6.24%
8.57%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVO vs. MRK — Risk-Adjusted Performance Rank
NVO
MRK
NVO vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NVO vs. MRK - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 1.74%, less than MRK's 3.10% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 1.74% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
MRK Merck & Co., Inc. | 3.10% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
Drawdowns
NVO vs. MRK - Drawdown Comparison
The maximum NVO drawdown since its inception was -71.31%, roughly equal to the maximum MRK drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for NVO and MRK. For additional features, visit the drawdowns tool.
Volatility
NVO vs. MRK - Volatility Comparison
Novo Nordisk A/S (NVO) has a higher volatility of 21.49% compared to Merck & Co., Inc. (MRK) at 4.82%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
NVO vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities